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Abstract
Background: 15% of multiple pregnancies ends in a preterm delivery, which can lead to mortality
and severe long term neonatal morbidity. At present, no generally accepted strategy for the
prevention of preterm birth in multiple pregnancies exists. Prophylactic administration of 17-alpha
hydroxyprogesterone caproate (17OHPC) has proven to be effective in the prevention of preterm
birth in women with singleton pregnancies with a previous preterm delivery. At present, there are
no data on the effectiveness of progesterone in the prevention of preterm birth in multiple
pregnancies.
Methods/Design: We aim to investigate the hypothesis that 17OHPC will reduce the incidence
of the composite neonatal morbidity of neonates by reducing the early preterm birth rate in
multiple pregnancies. Women with a multiple pregnancy at a gestational age between 15 and 20
weeks of gestation will be entered in a placebo-controlled, double blinded randomised study
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comparing weekly 250 mg 17OHPC intramuscular injections from 16–20 weeks up to 36 weeks of
gestation versus placebo. At study entry, cervical length will be measured. The primary outcome is
composite bad neonatal condition (perinatal death or severe morbidity). Secondary outcome
measures are time to delivery, preterm birth rate before 32 and 37 weeks, days of admission in
neonatal intensive care unit, maternal morbidity, maternal admission days for preterm labour and
costs. We need to include 660 women to indicate a reduction in bad neonatal outcome from 15%
to 8%. Analysis will be by intention to treat. We will also analyse whether the treatment effect is
dependent on cervical length.
Discussion: This trial will provide evidence as to whether or not 17OHPC-treatment is an
effective means of preventing bad neonatal outcome due to preterm birth in multiple pregnancies.
Trial registration: Current Controlled Trials ISRCTN40512715
Background
Despite the advances in neonatal care during the last dec-
ades, preterm birth remains the major cause of handicaps
in children without congenital anomalies. Prevention of
preterm birth is therefore a major goal of obstetric care.
However, strategies to prevent preterm birth have been
largely unsuccessful. Recently, it has been shown that pro-
phylactic progesterone administration in women with a
singleton pregnancy and a previous preterm birth signifi-
cantly reduces the incidence of preterm birth [1,2].
Incidence and financial impact of preterm birth
In women with singleton pregnancies, only 1% delivers
prior to 32 weeks. However, after previous preterm deliv-
ery this risk increases to 15% [3]. In both asymptomatic
singleton and twin pregnancies, a short cervical length is
predictive of preterm birth [4]. Multiple pregnancies are
by nature at high risk for preterm delivery. In the Nether-
lands approximately 15% of women with a multiple preg-
nancy delivers before 34 weeks of gestation [5-7]. At
present, approximately 1 in 60 pregnancies is a twin preg-
nancy, and around 30% of all preterm born children
admitted to a neonatal intensive care unit (NICU) are
from twin pregnancies [6,7]. The prevalence of twin preg-
nancies is still rising, partly due to an increase in age of
pregnant women and an increase in assisted reproductive
technologies. The financial burden of preterm born babies
is substantial: about € 1000, – per day when a child is
admitted to a NICU with the concomitant costs for both
parents and the society in general, in case the child is
handicapped.
Neonatal risks of preterm birth
Bad neonatal outcome includes respiratory distress syn-
drome (RDS), bronchopulmonary dysplasia (BPD), intra-
ventricular haemorrhage (IVH), periventricular
leucomalacia (PVL), necrotizing enterocolitis (NEC), sep-
sis and death before discharge [8]. The prevalence of this
poor neonatal outcome is 77%, 35% and 12% in children
born after early preterm delivery between 24–27, 28–32
and 32–34 weeks, respectively [7]. After 34 weeks this
incidence sharply declines to less than 2% at term. The
probability that a woman with a multiple pregnancy
delivers at these gestational ages is 1.8%, 5.4% and 7.2%,
respectively [6]. Overall, this means that about 8% of all
multiple pregnancies will result in the death of at least one
child, whereas in 7% of these pregnancies at least one of
the children will remain severely disabled. Moreover,
another 20% of the pregnancies will result in a moderate
handicap of at least one of the children.
Progesterone treatment for the prevention of preterm 
birth
Although preterm birth is known to be the most impor-
tant complication of multiple pregnancies, no commonly
accepted strategy is available to prevent this condition.
Progesterone administration (with a recently proven
effect on the occurrence of preterm birth in high risk sin-
gleton pregnancies [1,2,9]) is not as yet used. In conclu-
sion, no generally established strategy is at present
available to prevent the most common and important
complication of multiple pregnancies.
We propose an intervention with weekly progesterone
injections (250 mg 17 alpha hydroxyprogesterone
caproate (17OHPC)) from 16–20 weeks up to 36 weeks of
gestation. This intervention had been chosen for two rea-
sons. First, it has been proven that this prophylactic
administration of 17OHPC injections is effective in reduc-
ing the preterm birth rate in singleton pregnancies at high
risk for a spontaneous preterm delivery. Second, a multi-
ple pregnancy is considered to be a pregnancy at high risk
for a spontaneous early preterm delivery with a high com-
posite neonatal morbidity rate, as demonstrated by the
data shown above.
We choose to use intramuscular administration of proges-
terone over vaginal application, as we think that compli-
ance can be measured more accurately with the former
method.BMC Pregnancy and Childbirth 2007, 7:7 http://www.biomedcentral.com/1471-2393/7/7
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Safety of 17-alpha hydroxyprogesterone
In view of the disaster with diethylstilbestrol, it is under-
standable that many patients, doctors and others are con-
cerned about negative long term side effects on women or
their offspring [10]. 17-alpha-hydroxyprogesterone
caproate is a natural metabolite of progesterone that is
produced by the placenta itself. Apart from a painful spot
at the injection side, no side effects have been described
regarding the mother or child.
In the last 40 years progestins have been administered to
pregnant women for several reasons, including threaten-
ing miscarriage, recurrent miscarriage, threatening abor-
tion, prevention of preterm labour and luteal support
during IVF treatment. Especially for progestins with an
androgenic effect, there was fear for masculinisation of the
female foetus. Research among 2500 exposed women and
controls showed no difference with respect to the occur-
rence of abnormalities of the central nerve system, limbs
and joints, urogenital tract and circulatory tract between
treated and untreated pregnancies, even when 17OHPC
was administered in early pregnancy [11-13]. Also, long
term follow-up of prenatally exposed young adolescents
found no differences from controls with respect to
growth, onset of puberty, spatial and verbal test results
and sex-dimorphic behaviour and traits [14-16].
Methods/Design
Aims
The aim of this study is to investigate whether prophylac-
tic administration of 17OHPC will lower the incidence of
neonatal morbidity by reducing the number of preterm
births.
We will use a randomised, placebo-controlled double
blinded trial (the AMPHIA-trial: 17-Alpha hydroxyproges-
terone in Multiple pregnancies to Prevent Handicapped
InfAnts) to assess the effects of 17OHPC injections on
neonatal outcome. The study is set in the Dutch Obstetric
Research Consortium, a collaboration of obstetric prac-
tices in the Netherlands. Approximately 50 clinics, includ-
ing academic hospitals, non-academic teaching hospitals
and non-teaching hospitals will participate in this trial.
Participants/Eligibility criteria
All women with a multiple pregnancy, both mono- and
multichorionic, and a gestational age ≤ 19 weeks are eligi-
ble for participation in the AMPHIA-trial. Before inclu-
sion, chorionicity must be accurately determined by
means of ultrasound.
Women with a previous spontaneous preterm birth < 34
weeks, serious congenital defects or death of one or more
foetuses, early signs of twin-to-twin transfusion syndrome
or primary cerclage are excluded from the study.
Procedures, recruitment, randomisation and collection of 
baseline data
All women with a multiple pregnancy who present at one
of the participating clinics will be referred to an obstetri-
cian or a specifically appointed research nurse/midwife
for counselling. Eligible women will receive an informa-
tion sheet and, where possible, are given two weeks time
to reflect on participation. Once women have given con-
sent for the trial, they are randomised through a website,
according to a computer-generated randomisation
sequence. Stratification will be applied for chorionicity
(mono- versus multichorionic), number of multiples
(twin versus higher order multiple) and previous vaginal
birth (nullipara versus multipara). Randomisation will be
1:1 for progesterone and placebo.
When a patient is randomised, the company that supplies
the study medication will receive an automatic notifica-
tion by e-mail. A medication package with the corre-
sponding randomisation number, containing 20
ampoules of 1 cc of either 250 milligrams 17OHPC or
placebo, is then sent to the pharmacist in the clinic where
the patient has been randomised. After a maximum of 7
days, the medication package will be available to the
obstetrician or research nurse/midwife. Content of the
package is blinded to the practitioner, the patient and the
local pharmacist. In case of severe side-effects, allocation
can be disclosed by coded envelopes that are available to
the principal investigator.
Baseline demographic, past obstetric and medical histo-
ries will be recorded for all women. Cervical length will be
measured by transvaginal ultrasound at the time of ran-
domisation or at the next visit.
Intervention
The patient will receive the first intramuscular injection of
250 milligrams of 17OHPC or placebo at a gestational age
between 16+0 and 20+0 weeks. For the remaining duration
of the pregnancy, the medication package will be stored
by the patient herself. Weekly injections will be adminis-
tered by a nurse at the outpatient clinic, a general practi-
tioner or the patient herself. Dates of injection are noted
in a schedule that is kept both by the patient and in her
medical record. Non-compliance is defined as an interval
of more than ten days between two injections. Injections
are continued weekly until a gestational age of 36 weeks
or, in case of delivery before 36 weeks, until delivery.
Management of the pregnancy is done according to the
local protocol.
Follow up of women and infants
The patient will be invited for a final visit 6 weeks after
delivery. At this visit, all medication that has not beenBMC Pregnancy and Childbirth 2007, 7:7 http://www.biomedcentral.com/1471-2393/7/7
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used must be returned and the patient is asked about the
condition of her children.
All details of delivery, maternal assessments and admit-
tance during pregnancy are recorded in the case record
form that is accessible through the website. In case of
admittance of one or more children to the neonatal inten-
sive care unit, details of this admittance are also recorded.
Long-term follow up of children is desirable, but is
depending on future funding.
Outcome measures
The primary outcome measure is composite neonatal
morbidity. This composite morbidity rate contains severe
RDS, BPD, IVH grade II B or worse, NEC, proven sepsis
and death before discharge from the hospital [8].
Secondary outcome measures are time until delivery, pre-
term birth before 32 and 37 weeks, length of admission at
the neonatal intensive care unit, maternal morbidity, hos-
pitalization of the mother due to (threatened) preterm
labour and costs.
Analysis is performed according to the intention-to-treat
principle. The effectiveness of progesterone compared
with placebo will be assessed by calculating a relative risk
and 95% confidence interval. Time to delivery will be
assessed with Kaplan-Meier analysis and Cox propor-
tional hazard analysis. We will also assess whether there is
an interaction between treatment effect and cervical
length at 20 weeks.
Economic evaluation
General considerations
The aim of the economic evaluation is to compare the
optimality, in terms of costs and health effects, of weekly
(prophylactic) administration of 17OHPC progesterone
injections (16–20 to 36 weeks) with no intervention. As
the clinical study is based on a superiority design (it is
hypothesized that progesterone decreases preterm birth
considerably), the primary economic evaluation is a cost-
effectiveness analysis (CEA): the optimal strategy is the
one with the largest health gain at the smallest extra costs.
Costs and outcomes are analysed according to intention-
to-treat and described with appropriate statistical meas-
ures. The sensitivity of costs and health outcomes for var-
ious parameters is tested in sensitivity analysis. Scenario
analyses for relevant subgroups (e.g. gestational age at
birth, parity, monochorionic/dichorionic multiples) are
added.
Cost analysis
The process of care is distinguished into three cost stages
(antenatal stage, delivery/childbirth, postnatal stage) and
three cost categories (direct medical costs [all costs in the
health care sector], direct non-medical costs [costs outside
the health care sector that are affected by health status or
health care] and indirect costs [costs of sick leave]). For
each stage and each cost category, costs are measured as
the volumes of resources used multiplied with appropri-
ate valuations (cost-per-unit estimates, fees, national ref-
erence prices).
Cost volumes in the antenatal stage consist of direct med-
ical costs (e.g. hospital care, outpatient visits, administra-
tion of 17OHPC progesterone injections). Direct non-
medical and indirect costs in that stage may occur if role
patterns or household routines shift.
Costs during childbirth are dominated by the course of
childbirth and type of delivery. Cost volumes in the post-
natal stage consist of hospital-based maternal care (hospi-
talization etc.), neonatal care (admission to NICU/
medium care or maternity ward, related diagnostic care
and treatment, outpatient visits) and primary care. If neo-
natal health is suboptimal, further direct medical, direct
non-medical and indirect costs may occur. Hence, for
these infants, resource use of infants and/or parents is
measured during 12 months after childbirth.
Volumes of health care resource use are measured pro-
spectively alongside the clinical study in all participating
centres as part of the CRF.
Valuations of direct medical resources are estimated as
cost per unit estimates comprising "true economic" costs,
i.e. including shares of fixed costs and hospital overheads.
Costs per units are estimated for at least teaching and one
non-teaching hospital. An analysis based on reimburse-
ment fees is added. Direct medical volumes outside the
hospital and direct non-medical volumes are valued using
national reference prices [17]. Indirect costs are quantified
but remain unvalued. Study-specific costs are excluded
from analysis.
Statistical issues
Sample size
The sample size is calculated based on the primary out-
come 'bad neonatal outcome'. In the control group, 'bad
neonatal outcome' is expected in 7.2% of the children
(1.8%*77% + 5.4%*35% + 7.2%*12% + 35.6%*8% +
50%*.5% = 7.2%). In this calculation, the first rate repre-
sents the probability that a patient delivers at that gesta-
tional age, whereas the second rate represents the
probability of 'bad neonatal outcome' at that particular
gestational age. In case of treatment, 'bad neonatal out-BMC Pregnancy and Childbirth 2007, 7:7 http://www.biomedcentral.com/1471-2393/7/7
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come' is then expected in 3.9% of the children
(0.9%*77% + 2.7%*35% + 3.6%*12% + 17.8%*8% +
75%*.5% = 3.9%).
Because the outcomes in children from multiple pregnan-
cies are to a certain extent non-independent, we adjusted
our sample size assuming a correlation of 0.6 for compos-
ite neonatal morbidity between two children born from
the same pregnancy [18]. Using a two-sided test with an
alpha of 0.05 and a power of 0.80 we need 330 women in
the control group and 330 in the intervention group.
Data analysis
Data will initially be analysed according to the intention
to treat method. The main outcome variable, 'bad neona-
tal outcome', will be assessed by calculating rates in the
two groups, relative risks and 95% confidence intervals as
well as numbers needed to treat. To evaluate the potential
of each of the strategies, we will also perform a par proto-
col analysis, taking into account only those cases that were
treated according to protocol.
Time to delivery will be evaluated by Kaplan-Meier esti-
mates, with account for different durations of gestation at
entry, and will be tested with the log rank test. The other
secondary outcome measures will be approached simi-
larly to the primary outcome measure. The analysis will be
stratified for chorionicity, number of multiples and parity.
Furthermore, we will take account of non-independence
between children born from the same pregnancy using
cluster analysis.
Interim analysis
An interim analysis will be performed after the inclusion
of 300 women. This analysis will be done by an independ-
ent data and safety monitoring committee that will not be
aware of the allocation of treatment or placebo when they
judge data on effectiveness. In case of severe side-effects,
the safety monitoring committee can order to disclose the
label of patients with such side effects.
Ethical considerations
This study has been approved by the ethics committee of
the Academic Medical Centre Amsterdam (Ref. No. MEC
05/102) and by the boards of management of all partici-
pating hospitals.
Discussion
In the past, many strategies have been applied to prevent
preterm birth in multiple pregnancies, such as bed rest,
uterine activity monitoring, prophylactic tocolysis and
primary cerclage. However, none of these strategies have
been proven to be effective.
Whilst the aetiology of spontaneous preterm birth is mul-
tifactorial in both singleton and multiple pregnancies,
prophylactic administration of progesterone has recently
been shown to reduce preterm birth in women with a sin-
gleton pregnancy and a previous preterm delivery. From
that perspective, and taking into account the major medi-
cal and social implications of preterm birth, research has
to be done into the possible beneficial effects of progester-
one in multiple pregnancies.
Simultaneously with the AMPHIA-trial, a number of other
study groups in different countries have set up trials to
investigate the effectiveness of progesterone in preventing
preterm birth in multiple pregnancies. These are two trials
in the United States, one in Canada, one in Scotland, one
in Lebanon and one in Denmark [19-24]. Some of these
trials use intramuscular injection, analogously to this trial,
whilst others use vaginal application. If the outcome data
of these studies are pooled, a more conclusive statement
can be made on this matter.
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